De Motu Cordis is proud to be featured in the Saturday edition of the Courier Mail (March 15th, 2025).

De Motu Cordis grows its IP portfolio to 28 patents, fortifying innovations in emergency medicine for anaphylaxis with their drug-device dry powder inhaler.

De Motu Cordis CMO, Prof. John Fraser, awarded the Order of Australia for his contributions to medicine and critical care research.

De Motu Cordis (DMC) is pleased to acknowledge and enthusiastically commends the recent U.S. FDA approval of ARS Pharma's Neffy®, the first-ever needle-free intranasal epinephrine delivery device for the treatment of anaphylaxis.